header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

O2485 TEN YEARS FOLLOW-UP OF AN ANATOMICAL CEMENTLESS HYDROXYAPATITE COATED HIP PROSTHESIS (A.B.G.-I SYSTEM)



Abstract

Aims: The purpose of this study is to present our experience with the A.B.G.-I hip system after ten years follow-up. Methods: Prospective study about 162 hip prosthesis implanted from 1990 to 1992. We have assessed clinical and radiographic results immediately before surgery and at a minimum follow-up of ten years. Statistical analysis has been developed with S.P.S.S. Results: Sex distribution of the 162 initial prosthesis: 50.71% men and 49.29% women; affected side: right in 50.71%, left in 49.29%. First hip disease: rheumatoid arthritis in 7.48%, osteoarthritis in 77.57% and avascular necrosis in 14.95%. At this moment only 102 prosthesis continue on study: 8 revised (7.27%), 21 patients died (20.39%), 28 disappeared (17.18%) and 4 (2.45%) have not been considered. Clinical assessement let us be very satisþed, with a Merle DñAubigne score improving from 7.9 preoperative to 15.8 at ten years follow-up. Clinical results have been: excellent in 54.81%, good in 27.88% and bad in only 3.85%. Radiographic results are worse than expected: 84.11% of femoral stems developed some grade of stress shielding phenomenon and polyethylene inners wore excessively (mean value = 1.77 mm). The inßammatory response to polyethylene particles originated osteolytic lesions in 88.78% of femurs and 56.48% of periacetabular bones. Today 15.53% of patients in study are waiting for a revision. Conclusions: In spite of the very good clinical results, the radiographic assessement is very concerning. We think the þrst problem is the bad quality of polyethylene inner, that is responsible for grave osteolytic lesions.

Theses abstracts were prepared by Professor Dr. Frantz Langlais. Correspondence should be addressed to him at EFORT Central Office, Freihofstrasse 22, CH-8700 Küsnacht, Switzerland.